Get the Stockscreener App
212.45
0.47%
-1.01
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cardinal Health Inc stock is traded at $212.45, with a volume of 1.32M.
It is down -0.47% in the last 24 hours and up +7.36% over the past month.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
See More
Previous Close:
$213.46
Open:
$213.62
24h Volume:
1.32M
Relative Volume:
0.60
Market Cap:
$50.48B
Revenue:
$234.31B
Net Income/Loss:
$1.61B
P/E Ratio:
32.07
EPS:
6.6243
Net Cash Flow:
$4.45B
1W Performance:
+5.64%
1M Performance:
+7.36%
6M Performance:
+31.87%
1Y Performance:
+67.24%
1-Day Range:
$212.00
$214.52
1-Week Range:
$199.94
$215.48
52-Week Range:
$120.72
$215.48
Cardinal Health Inc Stock (CAH) Company Profile
Name
Cardinal Health Inc
Sector
Industry
Phone
(614) 757-3033
Address
7000 CARDINAL PLACE, DUBLIN, OH
Compare CAH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAH
Cardinal Health Inc
|
212.45 | 50.72B | 234.31B | 1.61B | 4.45B | 6.6243 |
|
MCK
Mckesson Corporation
|
840.46 | 104.19B | 387.09B | 4.23B | 6.01B | 32.12 |
|
COR
Cencora Inc
|
354.85 | 68.94B | 321.33B | 1.57B | 3.21B | 7.9518 |
|
HSIC
Henry Schein Inc
|
79.98 | 9.19B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.5902 | 840.28M | 2.22M | -5.63M | -1.68M | -0.24 |
Cardinal Health Inc Stock (CAH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Citigroup | Neutral → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-05-25 | Upgrade | Jefferies | Hold → Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Jan-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-06-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-13-24 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-09-24 | Upgrade | Argus | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Underweight |
| Jul-10-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-31-23 | Initiated | Citigroup | Neutral |
| Feb-03-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-04-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| May-26-22 | Downgrade | Barclays | Overweight → Equal Weight |
| May-18-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Underperform |
| May-10-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-21 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-25-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-20-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-20-20 | Upgrade | BofA/Merrill | Underperform → Buy |
| Feb-12-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-27-19 | Downgrade | Argus | Buy → Hold |
| Aug-20-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-18-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Nov-16-18 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Apr-24-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Apr-02-18 | Upgrade | Argus | Hold → Buy |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Underperform |
| Jan-05-18 | Initiated | Evercore ISI | In-line |
View All
Cardinal Health Inc Stock (CAH) Latest News
Cardinal Health, Inc. (CAH) shares gain favor as Citi turns bullish on specialist assets - MSN
Jim Cramer says “Cardinal is really the monster” among drug distributors - MSN
Cardinal Health Upgraded to Buy by Citi, Price Target Raised to $244 - Intellectia AI
Cardinal Health, Inc. (CAH) Shares Gain Favor as Citi Turns Bullish on Specialist Assets - Yahoo Finance
Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue? - sharewise.com
Cardinal Health (NYSE:CAH) Shareholders Will Want The ROCE Trajectory To Continue - Yahoo Finance
Procyon Advisors LLC Makes New Investment in Cardinal Health, Inc. $CAH - MarketBeat
Nordea Investment Management AB Increases Stake in Cardinal Health, Inc. $CAH - MarketBeat
Cardinal Health, Inc. $CAH Stake Reduced by Cairn Investment Group Inc. - MarketBeat
Dividend Stock Analysis: Cardinal Health, Inc. - Longbridge
Lobbying Update: $60,000 of CARDINAL HEALTH INC. lobbying was just disclosed - Quiver Quantitative
Buyback Watch: What is the earnings history of Cardinal Health IncGlobal Markets & Weekly High Return Stock Forecasts - baoquankhu1.vn
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report? - Finviz
Cardinal Health (NYSE:CAH) Sets New 1-Year High on Analyst Upgrade - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Cardinal Health (NYSE:CAH) Stock Price - MarketBeat
Wells Fargo Raises Price Target for Cardinal Health (CAH) to $23 - GuruFocus
Cardinal Health stock reaches all-time high at $214.93 By Investing.com - Investing.com Canada
Cardinal Health (NYSE:CAH) S&P 500 ETF Healthcare Infrastructure - Kalkine Media
Cardinal Health boosts profit forecast to $10/share, expands Publix deal - The Business Journals
Cardinal Health introduces ContinuCare™ Pathway; announces relationship with Publix - WebWire
10 Biggest Healthcare Companies - Investopedia
Cardinal Health raises 2026 profit forecast - WHTC
Leerink Partners Adjusts Price Target on Cardinal Health to $240 From $230, Maintains Outperform Rating - marketscreener.com
Baird Adjusts Price Target on Cardinal Health to $250 From $232, Maintains Outperform Rating - marketscreener.com
GRIMES & Co WEALTH MANAGEMENT LLC Purchases New Position in Cardinal Health, Inc. $CAH - MarketBeat
Why the Market Dipped But Cardinal Health (CAH) Gained Today - Yahoo Finance
Does Expanded Rapiblyk Distribution Hint at a Deeper Shift in Cardinal Health’s (CAH) Specialty Strategy? - Sahm
Key facts: Cardinal Health raises earnings outlook; completes drug deals; launches diabetes program - TradingView — Track All Markets
Cardinal Health Stock Jumps on Guidance Raise. Why 2026 Will Be a Good Year. - Barron's
Cardinal Health Inc (CAH) Stock Price Up 3.95% on Jan 13 - GuruFocus
Cardinal Health raises fiscal 2026 earnings outlook to at least $10 per share - Investing.com Canada
Cardinal Health (CAH) Raises FY26 Earnings Outlook, Shares Climb - GuruFocus
Why Is Cardinal Health Stock Gaining Tuesday?Cardinal Health (NYSE:CAH) - Benzinga
Cardinal Health (NYSE:CAH) Issues FY 2026 Earnings Guidance - MarketBeat
Cardinal Health (CAH) Boosts Earnings Expectations for 2026 - GuruFocus
Liberty One Investment Management LLC Acquires 217,826 Shares of Cardinal Health, Inc. $CAH - MarketBeat
Cardinal Health introduces ContinuCare Pathway alongside Publix partnership - Drug Store News
Cardinal Health beats with raised FY26 outlook (CAH:NYSE) - Seeking Alpha
Cardinal Health raises 2026 profit forecast on specialty drug demand - Reuters
Cardinal Health (CAH) Updates Fiscal Year 2026 Earnings Outlook - GuruFocus
Cardinal Health gains after raising 2026 profit forecast - TradingView — Track All Markets
(CAH) Cardinal Health Expects Fiscal 2026 Adjusted EPS At Least $10, vs. FactSet Est of $9.86 - marketscreener.com
Cardinal Health Inc Updates Fiscal 2026 Outlook and Strategic Initiatives - TradingView — Track All Markets
Cardinal Health Raises Fiscal 2026 Outlook and Highlights Strategic Progress During J.P. Morgan Healthcare Conference Presentation - Barchart.com
Tema Etfs LLC Makes New Investment in Cardinal Health, Inc. $CAH - MarketBeat
SG Americas Securities LLC Reduces Stock Position in Cardinal Health, Inc. $CAH - MarketBeat
Sterilization Services MarketGlobal Forecast 2025-2032: - GlobeNewswire
CPC Advisors LLC Makes New Investment in Cardinal Health, Inc. $CAH - MarketBeat
Should Value Investors Buy Cardinal Health (CAH) Stock? - sharewise.com
Will Analyst Upgrades and Specialty Focus Change Cardinal Health's (CAH) Healthcare Supply Chain Narrative? - Yahoo Finance
3 Medical Supplies Stocks That Beat the Market Despite Macro Headwinds - The Globe and Mail
Cardinal Health Inc Stock (CAH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
2.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):